These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 31955347)

  • 41. TCF7 knockdown inhibits the imatinib resistance of chronic myeloid leukemia K562/G01 cells by neutralizing the Wnt/β‑catenin/TCF7/ABC transporter signaling axis.
    Zhang H; Wang Y; Yang H; Huang Z; Wang X; Feng W
    Oncol Rep; 2021 Feb; 45(2):557-568. PubMed ID: 33416164
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Metabolic characterization of imatinib-resistant BCR-ABL T315I chronic myeloid leukemia cells indicates down-regulation of glycolytic pathway and low ROS production.
    Ko BW; Han J; Heo JY; Jang Y; Kim SJ; Kim J; Lee MJ; Ryu MJ; Song IC; Jo YS; Kweon GR
    Leuk Lymphoma; 2016 Sep; 57(9):2180-8. PubMed ID: 26854822
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways.
    Tang C; Schafranek L; Watkins DB; Parker WT; Moore S; Prime JA; White DL; Hughes TP
    Leuk Lymphoma; 2011 Nov; 52(11):2139-47. PubMed ID: 21718141
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).
    Lu T; Cao J; Zou F; Li X; Wang A; Wang W; Liang H; Liu Q; Hu C; Chen C; Hu Z; Wang W; Li L; Ge J; Shen Y; Ren T; Liu J; Xia R; Liu Q
    Eur J Pharmacol; 2021 Apr; 897():173944. PubMed ID: 33581133
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeted drugs in chronic myeloid leukemia.
    Gora-Tybor J; Robak T
    Curr Med Chem; 2008; 15(29):3036-51. PubMed ID: 19075651
    [TBL] [Abstract][Full Text] [Related]  

  • 46. TAL1 mediates imatinib-induced CML cell apoptosis via the PTEN/PI3K/AKT pathway.
    Wu Y; Hu Y; Yu X; Zhang Y; Huang X; Chen S; Li Y; Zeng C
    Biochem Biophys Res Commun; 2019 Nov; 519(2):234-239. PubMed ID: 31493871
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
    Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
    Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
    Lernoux M; Schnekenburger M; Losson H; Vermeulen K; Hahn H; Gérard D; Lee JY; Mazumder A; Ahamed M; Christov C; Kim DW; Dicato M; Bormans G; Han BW; Diederich M
    Clin Epigenetics; 2020 May; 12(1):69. PubMed ID: 32430012
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lyn regulates creatine uptake in an imatinib-resistant CML cell line.
    Okumu DO; Aponte-Collazo LJ; Dewar BJ; Cox NJ; East MP; Tech K; McDonald IM; Tikunov AP; Holmuhamedov E; Macdonald JM; Graves LM
    Biochim Biophys Acta Gen Subj; 2020 Apr; 1864(4):129507. PubMed ID: 31881245
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neferine in the Lotus Plumule Potentiates the Antitumor Effect of Imatinib in Primary Chronic Myeloid Leukemia Cells In Vitro.
    Zhang Y; Xiao Y; Dong Q; Ouyang W; Qin Q
    J Food Sci; 2019 Apr; 84(4):904-910. PubMed ID: 30866043
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New strategies in controlling drug resistance.
    Frame D
    J Manag Care Pharm; 2007 Oct; 13(8 Suppl A):13-7. PubMed ID: 17970610
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
    Aichberger KJ; Mayerhofer M; Krauth MT; Skvara H; Florian S; Sonneck K; Akgul C; Derdak S; Pickl WF; Wacheck V; Selzer E; Monia BP; Moriggl R; Valent P; Sillaber C
    Blood; 2005 Apr; 105(8):3303-11. PubMed ID: 15626746
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hyaluronan oligomers sensitize chronic myeloid leukemia cell lines to the effect of Imatinib.
    Lompardía SL; Díaz M; Papademetrio DL; Mascaró M; Pibuel M; Álvarez E; Hajos SE
    Glycobiology; 2016 Apr; 26(4):343-52. PubMed ID: 26582603
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib.
    Lee J; Shen P; Zhang G; Wu X; Zhang X
    Biomed Pharmacother; 2013 Mar; 67(2):157-63. PubMed ID: 23201011
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Real-time analysis of imatinib- and dasatinib-induced effects on chronic myelogenous leukemia cell interaction with fibronectin.
    Obr A; Röselová P; Grebeňová D; Kuželová K
    PLoS One; 2014; 9(9):e107367. PubMed ID: 25198091
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cantharidin Overcomes Imatinib Resistance by Depleting BCR-ABL in Chronic Myeloid Leukemia.
    Sun X; Cai X; Yang J; Chen J; Guo C; Cao P
    Mol Cells; 2016 Dec; 39(12):869-876. PubMed ID: 27989101
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CD-200 induces apoptosis and inhibits Bcr-Abl signaling in imatinib-resistant chronic myeloid leukemia with T315I mutation.
    Fang Z; Jung KH; Yan HH; Kim SJ; Son MK; Rumman M; Lee H; Kim KW; Yoo HD; Hong SS
    Int J Oncol; 2015 Jul; 47(1):253-61. PubMed ID: 25963192
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
    Scappini B; Gatto S; Onida F; Ricci C; Divoky V; Wierda WG; Andreeff M; Dong L; Hayes K; Verstovsek S; Kantarjian HM; Beran M
    Cancer; 2004 Apr; 100(7):1459-71. PubMed ID: 15042680
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The role of long noncoding RNA HOTAIR in the acquired multidrug resistance to imatinib in chronic myeloid leukemia cells.
    Wang H; Li Q; Tang S; Li M; Feng A; Qin L; Liu Z; Wang X
    Hematology; 2017 May; 22(4):208-216. PubMed ID: 27875938
    [TBL] [Abstract][Full Text] [Related]  

  • 60. p19
    Kuang Y; Han X; Cao P; Xiong D; Peng Y; Liu Z; Xu Z; Liang L; Roy M; Liu J; Nie L; Zhang J
    Blood Cells Mol Dis; 2020 Nov; 85():102477. PubMed ID: 32711219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.